Financial Tearsheet

Company Overview

Tenax Therapeutics Inc (NASDAQ:TENX)

Tenax Therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions.

Recent Financial News

Date	Headline
Apr 09, 2020	Tenax Therapeutics Announces Last Patient Completes Final Visit in its Phase 2 “HELP Study” of Levosimendan for Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction
Mar 12, 2020	Tenax Therapeutics Announces $2.75 Million Registered Direct Offering Priced At-the-Market
Mar 12, 2020	Tenax Therapeutics Completes Enrollment in Phase 2 Pulmonary Hypertension Trial
Feb 21, 2020	Tenax Announces the Addition of Mayo Clinic Expert, Dr. Barry Borlaug, to Scientific Advisory Board
Jan 13, 2020	Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial

Stock Performance

Today's Open	1.50
Volume	461,954
Day Range	1.40 - 1.57
52 Week Range	0.25 - 1.77
Bid/Ask	1.42 / 1.44
Bid/Ask Size	3,200 X 1,100
Previous Close	1.50
Market Cap	40.49 million
Shares Outstanding	28.12 million
Dividend/Yield	0.00 / 0.00%
EPS (TTM)	0.530103
P/E Ratio (TTM)	2.72

Recent XBRL Filings

Filing Date	Form Type	Description	View
May 15, 2020	10-Q	Quarterly report	html pdf xbrl
Mar 30, 2020	10-K	Annual report	html pdf xbrl
Nov 14, 2019	10-Q	Quarterly report	html pdf xbrl
Aug 14, 2019	10-Q	Quarterly report	html pdf xbrl
May 15, 2019	10-Q	Quarterly report	html pdf xbrl

Management Team

Michael B. Jebsen, Interim CEO, Chief Financial Officer

Douglas Hay, PhD, EVP of Regulatory Affairs

Nancy Hecox, EVP, Legal Affairs, General Counsel, and Corporate Secretary

Doug Randall, EVP of Commercial and Business Operations

Board of Directors

Dr. Ronald Blanck, Chairman

John Kelley, Chief Executive Officer

Anthony DiTonno, Director

James Mitchum, Director

Gregory Pepin, Director

Gerald Proehl, Director

Chris A. Rallis, Director